BioSpace News Archive

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 1:40 p.m. MST / 3:40 p.m. EST.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will present at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ, on Tuesday, November 13, 2018 at 8:35 A.M. (MT)

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and operating results.

Bristol Myers Squibb Company today announced that the U.S. Food and Drug Administration approved Empliciti injection for intravenous use

AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.

VentureMed Group, Inc., a medical device company that develops and markets innovative interventional vascular solutions, announced the initiation of a new study to determine if the FLEX Dynamic Scoring Catheter™ reduces dissections and the need for bailout stents in peripheral arteries.

A federal judge in California has ordered Australia-based Cochlear Corporation to pay more than $268 million to the Alfred E. Mann Foundation for Scientific Research (AMF) in a long-running patent dispute related to a hearing aid implant. U.S. Judge Fernando M. Olguin reinstated a jury award of $134 million and granted AMF’s motion for enhanced damages due to a finding of willful infringement by Cochlear, doubling the jury’s damages award.

Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation’s leading health systems and physician organizations, today announced financial results for the quarter ended September 30, 2018.

Personalis, Inc. will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.